232
Participants
Start Date
February 11, 2019
Primary Completion Date
November 16, 2022
Study Completion Date
November 16, 2022
PRT543
PRT543 will be administered orally
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, The Bronx
UPMC Hillman Cancer Center, Pittsburgh
Thomas Jefferson University Hospital, Philadelphia
Christiana Care Health Services, Christiana Hospital, Newark
Levine Cancer Institute, Charlotte
Georgia Cancer Center at Augusta University, Augusta
Florida Cancer Specialists, Lake Mary
Moffitt Cancer Center, Tampa
Florida Cancer Specialist, Sarasota
PLLC, Nashville
Norton Cancer Institute, St. Matthews Campus, Louisville
The Ohio State University and Wexner Medical Center, Columbus
University of Michigan, Ann Arbor
University of Iowa Hospitals and Clinics, Iowa City
Ochsner Clinic Foundation, New Orleans
MD Anderson Cancer Center, Houston
Banner MD Anderson Cancer Center, Gilbert
UCSF Precision Cancer Medicine Building, San Francisco
Seattle Cancer Care Alliance, Seattle
Dana Farber Cancer Institute, Boston
Atlantic Health System / Morristown Medical Center, Morristown
The University of Texas MD Anderson Cancer Center, Houston
Lead Sponsor
Prelude Therapeutics
INDUSTRY